Sunday, March 9
HIV DISEASE: CHEMOTHERAPY AND PATHOGENESIS
Monday, March 10
EVENTS IN ACUTE INFECTION AND EARLY DISEASE
D. Ho, Discussion Leader
- G. Panteleo - "Analysis of immune response during primary HIV infection"
- L. Corey - "Setting expectations from early therapy"
- M. Markowitz - "Treatment of early HIV infection"
Poster Session
VIRUS BINDING, ENTRY AND ASSEMBLY
E. Berger, Discussion Leader
- E. Berger - "HIV entry and tropism: the chemokine receptor connection"
- G. Henson - "Mechanism of action of the anti-HIV bicyclam, AMD 3100: new studies suggest how it blocks viral entry and fusion"
- T. Schall - "Cloning and functional characterization of a novel chemokine receptor from human dendritic cells"
- S. Gracheck - "Benzamide sulfides: anti-HIV compounds that act early in the HIV replication cycle"
Tuesday, March 11
NEW ANTIVIRALS
D. Kempf, Discussion Leader
- B. Larder - "New antiretrovirals in development at Glaxo Wellcome"
- N. Bischofberger - "PMPA and its orally bioavailable prodrug bis(POC)PMPA: preclinical evaluation and clinical status"
- H. Sham - "The design, synthesis and biological properties of ABT-378, a new HIV protease inhibitor"
- S. Thaisrivongs - "Dihydropyrone - a third generation HIV protease inhibitor"
Poster Session
STRUCTURE BASED DESIGN
E. Arnold, Discussion Leader
- M. Summers - "NMR studies of HIV-1 gag proteins: defining new targets for antiviral strategies"
- S. Hughes - "HIV -1 RT: why template-primer positioning is important for enzymatic function and drug resistance"
- J. Vacca - "Design of HIV protease inhibitors"
- J. Erickson - "Towards the design of resistance-repellant protease inhibitors: fact or fantasy?"
Wednesday, March 12
EMERGING IMMUNE-BASED THERAPIES
N. Sarver, Discussion Leader
- D. Weiner - "Engineering DNA vaccines for HIV-1"
- M. Sykes - "Xenogeneic thymic replacement"
- J. Lieberman - "Immunotherapy with ex-vivo expanded HIV-specific cytotoxic T lymphocytes"
- J. Zaia - "Gene therapy of AIDS using autologous hematopoietic stem cells"
- G. Milman - "How you can benefit from $250 million in NIH small business grants"
COMBINATION CHEMOTHERAPY IMPACT ON CLINICAL TRIAL DESIGN
R. Behrman, Discussion Leader
- R. Yarchoan - "Development of novel anti-HIV agents in the era of effective combination chemotherapy"
- R. Schooley - "Combination therapy: current status and remaining challenges"
Thursday, March 13
TARGETING HIV CELLULAR COFACTORS
G. Tarpley, Discussion Leader
- M. Stevenson - "Regulation of HIV/SIV infectivity by cellular kinases"
- M. Emerman - "HIV-mediated cell cycle arrest"
- A. Heguy - "Anti-rev drug discovery"
- F. Lori - "Targeting a cellular factor (by hydroxyurea) as part of a promising alternative for treating HIV-1 infection before and after seroconversion"
VACCINE AND PREVENTION STRATEGIES UPDATE
C. Dieffenbach, Discussion Leader
- D. Bolognesi - "Searching for surrogates of immune correlates"
- C. Miller - "Use of vaginal microbicides to prevent heterosexual transmission of HIV: efficacy tests in the SIV/rhesus monkey model"
|